CHI Interviews Janet L. Lathey, Ph.D of Emergent BioSolutions on Optimizing Bioassays for Biologics
Needham, MA, August 26, 2013 --(PR.com
)-- Janet L. Lathey, Ph.D., Director, Immunology and Assay Development, BioDefense Division, Emergent BioSolutions sits down with conference producer Samantha Lewis to discuss the biggest challenges to managing bioassay variability, new tools and strategies that researchers are using to combat it, and how procedural variation can have unwanted repercussions. Dr. Lathey will be presenting her talk, "Evaluation of Processes for Reducing and Monitoring Assay Variability for Bioassays," at the inaugural Optimizing Bioassays for Biologics conference. Register and hear presentations from 15 international thought-leaders in bioassays for biologics.
To listen to this exclusive podcast visit: immunogenicitysummit.com/imn_content.aspx?ekfrm=12888
About the Conference:
Bioassays are a critical component of biologics drug discovery and development. However, ever-changing technology, approaches, and regulatory requirements make it difficult to keep projects on track and on budget. Cambridge Healthtech Institute’s Inaugural Optimizing Bioassays for Biologics will bring together key individuals from bioanalytical R&D, cell and antibody engineering, immunology, pharmacology, and preclinical and clinical development. Special focus will be given to the development and validation of potency assays, developing bioassays for multi-domain proteins, and establishing a standard for using cell-based vs. non-cell-based assays. Regulatory updates, expectations for novel constructs, and reference standards will also be shared.
About the Summit:
Get ready to join 300+ of your peers on November 11-13, 2013 in Washington, DC at the Number 1 Immunogenicity Summit in the U.S. CHI has an established reputation as a global education provider on immunogenicity. Our 2013 summit will build on last year’s successful event. With double the number of tracks this year, the Immunogenicity Summit 2013 presents technologies for safety and efficacy from bench to bedside. For early stage decision making on drug design and optimization, we examine the causes of immunogenicity together with means of mitigation, and present PK/PD and bioassay strategies. For later pre-clinical and clinical stages, we examine the complexities of immunogenicity assays, bioassays and PK/PD development, and present risk assessment strategies for smooth interaction with the regulatory authorities, and safe and efficacious products in the clinic.
For more information visit ImmunogenicitySummit.com